Skip to main content
OpenTrials
Recruiting

NCT Number: NCT03703271

Study of Hysteroscopic Repeat Curettage as the First-line Treatment in Low-risk Postmolar Gestational Trophoblastic Neoplasia

Study of hysteroscopic repeat curettage as the first-line treatment in low-risk postmolar gestational trophoblastic neoplasia compared with the MTX single drug chemotherapy

Recruiting

Interested in participating?

Request Info

Key information

Age range

12 year–60 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 3

Primary location

Weiguo Lv

Hangzhou, Zhejiang, 310006, China

Location status: Recruiting

Location contact

Weiguo Lv, Doctor

CONTACT

[email protected]

13588193832

About this study

Gestational trophoblastic neoplasia (GTN) is a group of malignant tumors derived from placental trophoblastic cells, most of which are secondary to hydatidiform mole, and 95% of GTN patients present low-risk gestational trophoblastic neoplasia(LR-GTN).In the 1960s and 1970s, with the in-depth study of the disease, it was found that the malignant tumor was highly sensitive to chemotherapy and had ideal tumor marker HCG to guide the treatment and follow-up. Therefore, GTN was the best malignant tumor with the overall cure rate of LR-GTN nearly 100%.MTX single-drug multi-course chemotherapy is the classic treatment of LR-GTN recommended by FIGO, but most patients can develop gastrointestinal, blood and liver toxicity during chemotherapy. In addition, the longer treatment cycle also brings a lot of discomfort to patients.

In recent years, some scholars proposed that the selection of treatment regimen of LR-GTN secondary to hydatidiform pregnancy should consider the toxic and side effects of chemotherapy, the maintenance of patients' physiological functions and quality of life.Retrospective studies abroad have shown that LR-GTN delayed chemotherapy for hydatidiform mole pregnancy only started chemotherapy for LR-GTN at a certain stage of progression, and the results did not change the prognosis of LR-GTN but reduced the rate of chemotherapy.In addition, for some patients with ultra-low risk of LR-GTN in hydatidiform pregnancy undergoing hysteroscopic repeat curettage , the rate of chemotherapy can be reduced, the related costs can be reduced and the quality of life of patients can be improved.

In this non-Inferiority prospective, multicenter, randomized, controlled clinical study, with the routine use of a gleam of MTX single drug treatment scheme for comparison, comparing uterine cavity again emptying delay chemotherapy guided by parallel hysteroscopy surgery clinical curative effect and adverse reaction, which discuss after hydatidiform mole ultra-low dangerous GTN patients with uterine cavity emptying again guided by hysteroscopy surgery as a line of ultra low dangerous GTN patients after hydatidiform mole security and feasibility of the treatmen

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • low-risk postmolar gestational trophoblastic neoplasia (GTN)
  • World Health Organization(WHO) risk score≤4
  • Age≤60 years; female, Chinese women
  • Initial treatment
  • Performance status: Karnofsky score≥60
  • Laboratory tests: WBC≥3.5×10(9)/L, ANC≥1.5×10(9)/L, PLT≥80×10(9)/L, serum bilirubin≤ 1.5 times the upper limit of normal, transaminase≤ 1.5 times the upper limit of normal,blood urea nitrogen, Cr≤ normal
  • Provide written informed consent.

Exclusion criteria

  • Patients with unconfirmed diagnosis of GTN
  • Patients with placental-site trophoblastic tumor (PSTT) or epithelioid trophoblastic tumor (ETT)
  • WHO risk score ≥5分
  • The diameter of a single metastatic lesion in the lung was ≥2cm
  • The number of lung CT metastases was≥ 5
  • With severe or uncontrolled internal disease, unable to receive chemotherapy
  • Concurrently participating in other clinical trials
  • Unable or unwilling to sign informed consents
  • Unable or unwilling to abide by protocol

Treatment and study plan

methotrexate

Drug

single-agent 5-day methotrexate, two weeks a cycle

Other names: Methotrexate chemotherapy

hysteroscopic repeat curettage

Procedure

Study of Hysteroscopic Repeat Curettage as the First-line Treatment in Low-risk Postmolar Gestational Trophoblastic Neoplasia

Other names: complete curettage

Primary outcomes

  1. The ultimate complete response rate

    Time frame: 2 years

    The investigators may calculate the ultimate complete response rate, defined as the proportion of patients who achieve sustained normalisation of serum hCG without requiring escalation to multi-agent chemotherapy at the predefined trial endpoint.

Secondary outcomes

  1. chemotherapy-sparing rate

    Time frame: 2 years

    The investigators may calculate the rate of response after the initial treatment of hysteroscopic repeat curettage without chemotherapy

  2. Complications of hysteroscopic repeat curettage surgery

    Time frame: 2 years

    The investigators may record the complications of hysteroscopic repeat curettage surgery

  3. Severity of adverse events as assessed by the WHO

    Time frame: 2 years

    The investigators may record the adverse events of chemotherapy as assessed by the WHO

  4. Overall Survival Rate (OR)

    Time frame: 2 years

    Overall Survival Rate of the two group patients

  5. Ovarian functional evaluation

    Time frame: 2 years

    The investigators may test serum level of anti-mullerian hormone (AMH) every 6 months.

  6. The pregnancy rate

    Time frame: 2 years

    To calculate the pregnancy rate in an actuarial manner using the Kaplan-Meier method at the end of the trail

  7. Menstrual cycle resuming rate

    Time frame: 2 years

    The investigators record the time of menstrual cycle resuming after chemotherapy

Sponsors and collaborators

Lead sponsor

Women's Hospital School Of Medicine Zhejiang University

Other

Collaborators

  • Huazhong University of Science and Technology
  • Qilu Hospital of Shandong University
  • Sun Yat-sen University

Registry information

Official study title

A Non-Inferiority Prospective Randomized Multicenter Clinical Control Study of Hysteroscopic Repeat Curettage as the Primal Management of Low-risk Postmolar Gestational Trophoblastic Neoplasia

Important dates

Study start
2019
Primary completion
2026
Study completion
2026
First posted
Oct 11, 2018
Registry last updated
Jul 1, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.